<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010046</url>
  </required_header>
  <id_info>
    <org_study_id>ANX005-CP01</org_study_id>
    <nct_id>NCT03010046</nct_id>
  </id_info>
  <brief_title>Single Dose Study of ANX005 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-controlled, Double Blind, Single, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled, ascending,
      single-infusion, sequential group study. Single, ascending doses will be administered to
      approximately 64 subjects, with an option for 1 additional multi-dose cohort in approximately
      8 subjects. The primary objective is to evaluate the safety of ANX005 administered as an
      intravenous infusion as a single agent and in combination with intravenous immunoglobulin
      (IVIg). The optional multi-dose cohort will evaluate either additional subjects at the
      maximum tolerated dose or ANX005 administered as 2 infusions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Day 43</time_frame>
    <description>Safety is assessed throughout the study. Day 43 is the last visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine effective dose of ANX005</measure>
    <time_frame>Day 43</time_frame>
    <description>Percent of subjects with a biologic response, defined as a reduction of serum CH50 percent change from baseline at 21 and 28 days after the first ANX005 infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Explore relationship of AUC with PD responses in serum</measure>
    <time_frame>Day 43</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Explore relationship of AUC with PD responses in CSF</measure>
    <time_frame>Day 43</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Explore relationship of half-life with PD responses in serum</measure>
    <time_frame>Day 43</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Explore relationship of half-life with PD responses in CSF</measure>
    <time_frame>Day 43</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Safety and Tolerability in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ANX005 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANX005 intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX005 and IVIg Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX005</intervention_name>
    <description>Single ascending dose intravenous infusion</description>
    <arm_group_label>ANX005 Monotherapy</arm_group_label>
    <arm_group_label>ANX005 and IVIg Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIg</intervention_name>
    <description>IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.</description>
    <arm_group_label>ANX005 and IVIg Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>0.9% saline intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females 18 years and older

          -  Females must be postmenopausal, surgically sterilized, or willing and able to use 2
             methods of contraception throughout the study and for 1 month after the final study
             visit

          -  Willing and able to undergo vaccination if not vaccinated recently

        Exclusion Criteria:

          -  History of any autoimmune disease, meningitis, septicemia or pneumonia

          -  History of hypercoagulable diseases, hyperviscosity, thrombosis, renal dysfunction or
             acute renal failure

          -  Known genetic deficiencies of the complement cascade system

          -  History of conditions whose symptoms and effects could alter protein catabolism or IgG
             utilization, e.g. protein-losing enteropathies or nephrotic syndrome

          -  Body weight less than 50 kg or greater than 100 kg

          -  Hypersensitivity or allergic reactions to any excipients in the ANX005 drug product

          -  (Cohorts 4b and 5b) Known selective IgA deficiency or presence of antibodies to IgA at
             screening

          -  (Cohorts 4b and 5b) Prior reaction or hypersensitivity to blood products, including
             IVIg or any of the excipients in IVIg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandy Calman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Annexon Medical Monitor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Lickliter, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Wong</last_name>
    <phone>61-3-9076-8902</phone>
    <email>e.wong@nucleusnetwork.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Kendall</last_name>
    <phone>650-822-5511</phone>
    <email>laura@annexonbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Lickliter, MBBS PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

